Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02405026|
Recruitment Status : Completed
First Posted : April 1, 2015
Last Update Posted : October 3, 2017
|Condition or disease|
Prospectively clinically phenotype and the prevalence of asthma in HIV infected patients in the Duke ID Clinic
- HIV infected asthmatic subjects meeting clinical definitions for asthma compared to HIV uninfected asthma subjects identified at the DAAAC and HIV infected non-asthmatic subjects.
- Prospective immunological phenotyping - HIV-infected asthma subjects prospectively identified and clinically phenotyped compared to HIV-uninfected asthma subjects identified at the DAAAC and HIV infected non-asthma subjects.
Regarding the sampling method of probability sample: All samples for HIV infected asthmatic patients, HIV uninfected asthmatic patients and HIV infected non-asthmatics patients will be analyzed.
Retrospectively determine overall asthma prevalence and severity among HIV-infected patients. Retrospective immunological phenotyping (circulating cytokines) of HIV-infected patients utilizing available specimens in the Duke HIV Specimen Biorepository
- HIV-infected asthmatic subjects meeting asthma definition compared to overall asthma prevalence in U.S. population
- HIV-infected asthma subjects meeting asthma definitions compared to matched HIV-infected non-asthma subjects
|Study Type :||Observational|
|Actual Enrollment :||83 participants|
|Official Title:||HIV and Asthma in the Post-ART (Antiretroviral Therapy) Era|
|Study Start Date :||December 2014|
|Actual Primary Completion Date :||July 2017|
|Actual Study Completion Date :||July 2017|
HIV infected patients
HIV infected patients with asthma
HIV uninfected patients
HIV uninfected patients with asthma
HIV infected non-asthmatic patients
HIV infected patients without asthma
- Asthma prevalence of HIV infected subjects currently followed at the Duke Infectious Disease (ID) Clinic compared to HIV uninfected asthma subjects identified at the Duke Asthma, Allergy and Airway Center (DAAAC). [ Time Frame: 12 months ]Assessed through Asthma control questionnaire, pulse oximetry, FeNO, Spirometry, Methacholine challenge, Induced sputum for differential, serum periostin, questionnaires
- Asthma phenotypic characteristics of HIV infected subjects compared to HIV uninfected asthma subjects and HIV infected non-asthmatic subjects. [ Time Frame: 12 months ]Assessed through blood collection
- Prospective immunological phenotyping of Th1/Th2/Th17 cytokines and T cell subsets [ Time Frame: 12 months ]Assessed through blood sample collection
- Retrospective immunological phenotyping (circulating cytokines) of HIV-infected patients utilizing available specimens in the Duke HIV Biorepository [ Time Frame: 12 months ]The primary measure of is the quantitative difference in IL-6 between HIV-infected asthmatic subjects and HIV-infected non-asthmatic subjects.
- Retrospectively determine overall asthma prevalence among HIV-infected patients [ Time Frame: 12 months ]HIV-infected asthmatic subjects meeting electronic health records asthma definition Compared overall asthma prevalence in U.S. population.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02405026
|United States, North Carolina|
|Duke Asthma Allergy and Airway Center|
|Durham, North Carolina, United States, 27705|
|Principal Investigator:||Loretta Que, MD||Duke University|